Mineralys Therapeutics, Inc. (MLYS)

Latest News

Jun 8, 2026

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Jun 3, 2026

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Jun 3, 2026

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

View All News

Corporate Presentation

May 6, 2026

Mineralys Corporate Overview May 2026

View Presentation View All Presentations

Latest Event

Jun 3, 2026 7:35 am EDT

Jefferies Global Healthcare Conference

View Event View All Events

Latest Financial Results

Q1 2026

Quarter Ended Mar 31, 2026

Earnings Release

HTML PDF

Earnings Webcast

Audio

10-Q

HTML PDF

XBRL

ZIP

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

Company Overview

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com.

View Executive Team View Board of Directors

Contact Information

Company

Mineralys Therapeutics, Inc.
150 N. Radnor Chester Rd
Suite F200
Radnor, PA 19087
United States
Toll-Free: 888-378-6240

Investor Relations

investorrelations@mineralystx.com

Transfer Agent

American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, New York 11219
United States
T: 800-937-5449
F: 718-236-2641
help@astfinancial.com
https://www.astfinancial.com

Media

Elixir Health Public Relations
Melyssa Weible
T: 201-723-5805
mweible@elixirhealthpr.com